ZFIN Image: Yang et al., 2023, Fig. 4

Image

Figure Caption

Fig. 4

Combination of Roblitinib and CPI-169 elicits robust anti-cancer effects in vivo. A-C Subcutaneous xenograft tumors established from SMMC-7721 cells were treated with vehicle or the indicated drugs. Shown are the tumors (A), tumor weight (B) and the tumor volume (C) from the recipient mice. Mice with SMMC-7721 xenografts were treated with vehicle (n = 6), CPI-169 (n = 6), Roblitinib (n = 6) or CPI-169 + Roblitinib (n = 6) for 2 weeks. Scale bars: 1 cm. Values are presented as mean � SEM; One-way ANOVA with Tukey?s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. D Representative H&E and IHC staining for H3K27me3, phospho-FGFR4 (p-FGFR4), Ki67 and Cleaved caspase-3 (cl. Caspase 3) in tumors. Scale bars: 50 ?m. The intensity of Ki67 and Cleaved caspase-3 staining cells were quantified. Values are presented mean � SEM; One-way ANOVA with Tukey?s multiple comparisons test, ***p < 0.001, ****p < 0.0001

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Exp. Clin. Cancer Res.